PLx Pharma Inc. Reports Second Quarter 2018 Results

HOUSTON, TX and VANCOUVER, Dec. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSXV:EPI, NASDAQ:EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corpo.....»»

Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results.....»»

HAIKOU CITY, China, Nov. 15, 2018 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," the "Company" or "We"), an NYSE American listed corporation with a fully.....»»

PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on commerciali.....»»

- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCo.....»»

Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update Enrolled more than 95% of .....»»

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fisca.....»»

HOUSTON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company focused on c.....»»

ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance Acquires WellSpring Pharma Services for $18 Million in Cash to Expand Contract Manufacturing Business and Accelerate ANDA Pipeline .....»»

CONSHOHOCKEN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharma.....»»

- Continued.....»»

Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update More than 350 patients enrolled in pivotal Phase 3 A.....»»

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fisc.....»»

NDA submission for Gimoti™ on track for second quarter of 2018 Announced.....»»

HOUSTON, May 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceu.....»»

MEI Pharma Reports Third Quarter Fiscal Y.....»»

Recro Pharma Reports First Quarter 2018 Financial Results.....»»

First Half Year of Fiscal Year 2019 Financial Highlights Non-GAAP net income attributable to Hollysys was $72.4 million, an increase of 24.3% co.....»»

DES MOINES, Iowa, Feb. 15, 2019 (GLOBE NEWSW.....»»

-$0.04/share for the 12.....»»